{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 41,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 56,
  "notes": "Data cutoff 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/27",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.89
      },
      "kind": "disclaimer",
      "text": "Data cutoff 23MAR2023 / * Related to ERAS-007. EC: encorafenib 300 mg oral daily + cetuximab 500 mg/m² intravenous infusion once every 2 weeks. ERAS-007 QW: ERAS-007 oral once a week. ERAS-007 BID-QW: ERAS-007 oral twice a day on a single day each week.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7450a62f-9def-4837-bf9e-edab1b7d1b85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "list",
      "text": "No Grade 4 or 5 TRAEs were observed. ERAS-007 100 mg BID-QW dose is being expanded in combination with approved doses of EC to assess signals of efficacy in patients with EC-naïve BRAF V600E mCRC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "719d4a56-eab0-420a-9970-cf991de9d61f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.94,
        "x": 0.03,
        "y": 0.24
      },
      "kind": "table",
      "text": "Table showing Fatigue, Diarrhea, Headache, Anaemia, Nausea, Subretinal fluid, Vomiting across 150mg QW, 75mg BID-QW, 100mg BID-QW, and ALL cohorts.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6704fa56-48e0-4102-8478-82b6d77ca803",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "ERAS-007 + EC was generally well tolerated with primarily Grade 1 or 2 TRAEs observed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37ecd7d2-68c7-4c0a-ab8a-193e9a525e57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.19,
        "y": 0.15
      },
      "kind": "title",
      "text": "Treatment-related* Adverse Events Reported in ≥ 20% of All Patients (arranged by descending frequency in the ALL Any Grade column)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36d8e6e3-cd3f-45b2-9abc-129e5aaca889",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "f9603ee5-a589-468f-8e3d-07c5b60bb405",
      "evidence": "table/data: Table showing Fatigue, Diarrhea, Headache, Anaemia, Nausea, Subretinal fluid, Vomiting across 150mg QW, 75mg BID-QW, 100mg BID-QW, and ALL cohorts.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "Describing the potential benefits of Erasca's pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}